TwitterLinkedin

Contact Us

  • Biopharma Excellence
  • News & Events
    • Industry News Articles
    • Press Releases
    • Webinars
    • Events
    • Blog
    • Podcasts
  • Resource Library
    • Thought Leadership
    • Fact Flyers
    • Case Studies
    • White Papers
    • Webinars
    • Infographics
    • Video & Animation
  • Careers
    • Life at PharmaLex
    • Current Opportunities
  • Training
Top Bar
Search
PharmaLex Logo
MENUMENU
  • PharmaLex Logo
  • PharmaLex Logo
  • About UsAbout Us
    • About Us
    • Management Team
    • Corporate Social Responsibility
    • What Our Clients Say About Us
  • Our Services
    • Discovery / Non-clinical
          • Go to Discovery / Non-clinical section >>

          • Strategy and Consulting

            • Integrated Product Development
            • Market Access
            • Scientific Advice
            • Statistics and Data Sciences
            • Toxicology Services
    • Clinical Development
          • Go to Clinical Development section >>

          • Strategy and Consulting

            • Clinical Program Development
            • Scientific Advice
            • Statistics and Data Sciences
          • Regulatory Affairs

            • Clinical Trial Applications
            • Global Procedure Management
            • Health Authority / Agency Interaction
            • Regulatory Operations
          • Pharmacovigilance

            • Clinical Trial Safety Support
            • Pharmacovigilance Consulting
          • Quality

            • GxP Services
            • Interim / Contract QA
            • Quality Management Systems
            • Tech Transfer / Scale-up
    • Authorization / Approval
          • Go to Authorization / Approval section >>

          • Strategy and Consulting

            • Market Access
          • Regulatory Affairs

            • CMC Services
            • Global Procedure Management
            • Health Authority / Agency Interaction
            • Marketing and Labeling Activities
            • Regulatory Operations
            • Scientific, Regulatory and Technical Writing
            • Statistics and Data Sciences
          • Pharmacovigilance

            • EU QPPV / National QPPV
            • Pharmacovigilance Consulting
          • Quality

            • Commercialization Readiness
            • Commissioning, Qualification, and Validation (CQV)
            • GxP Services
            • Interim / Contract QA
            • PAI Readiness
    • Post-approval / Maintenance
          • Go to Post-approval / Maintenance section >>

          • Strategy and Consulting

            • Market Access
          • Regulatory Affairs

            • CMC Services
            • Global End-to-End Outsourcing
            • Global Procedure Management
            • Health Authority / Agency Interaction
            • Marketing and Labeling Activities
            • Mergers and Acquisitions (M&A) Transfers
            • Regulatory Operations
            • Toxicology Services
          • Pharmacovigilance

            • EU QPPV / National QPPV
            • ICSR (Individual Safety Case Report) Management
            • Literature Monitoring & Screening
            • Pharmacovigilance Quality & Compliance
            • Signal Management
          • Quality

            • Commissioning, Qualification, and Validation (CQV)
            • GxP Services
            • Interim / Contract QA
            • Quality Management Systems
          • Medical Affairs

            • Healthcare Compliance and Medical Approval
    • Program Management
          • Go to Program Management section >>

          • Program Management

            • Global End-to-End Outsourcing
            • Global Procedure Management
            • Integrated Product Development
            • Mergers and Acquisitions (M&A) Transfers
    • Featured Expertise
          • Industry Expertise

            • Biopharmaceuticals
            • MedTech Services
          • Service Expertise

            • ATMP / Cell and Gene Therapy
            • COVID-19 Support
            • GxP Services
            • Market Access
            • Pharmacovigilance Consulting
            • Post-Brexit Regulatory Support
            • Statistics and Data Sciences
            • SMARTPHLEX - technology-enabled services
  • Global ReachGlobal Reach
  • Contact usContact us
  • News & Events
    • Industry News Articles
    • Press Releases
    • Webinars
    • Events
    • Blog
    • Podcasts
  • Resource Library
    • Thought Leadership
    • Fact Flyers
    • Case Studies
    • White Papers
    • Webinars
    • Infographics
    • Video & Animation
  • Careers
    • Life at PharmaLex
    • Career Opportunities
  • Training
Home > News & Events > Ireland > 5-Key Elements of a Cleaning Validation Study

5-Key Elements of a Cleaning Validation Study

The Pharmaceutical industry cannot afford to compromise on cleanliness. Product contamination results in wasted effort and resources, or worse, creates health and safety issues that can compromise a company’s reputation and customer confidence. What are the various elements of a basic cleaning validation study? DETERMINE THE MOST APPROPRIATE CLEANING PROCEDURE FOR THE EQUIPMENT Generate acceptance criteria data for the contaminant. The cleaning validation must demonstrate that the procedure consistently removes residues of the substance previously manufactured down to levels that are acceptable. In addition, it must be demonstrated that the cleaning procedure itself does not contribute unacceptable levels of residual materials to the equipment. The limits set should be practical, justifiable and achievable. In Active Pharmaceutical Ingredient manufacture there may be partial reactants and unwanted by-products which may not have been chemically identified. Therefore, it may be necessary to focus on by-products as well as the principle reactant. Companies should decide on which residue(s) to quantify based on sound scientific rational. The cleaning method will be determined by the process, the equipment, the cleaning agents and the cleaning techniques available. Cleaning Methods Determination: Cleaning in Place (CIP) Systems while requiring a greater capital investment initially are of course less labour intensive, have no disassembly or reassembly and produce highly repeatable results. In addition, they are deemed safer for workers with less chemical exposure and effectively help to manage water and chemical costs. Cleaning out of Place (COP) Systems would be employed in situations where process equipment needs to be disassembled for cleaning, typically equipment that is small, complex, or difficult to clean. COP systems can also be used in conjunction with manual cleanings when a CIP system isn’t in the budget. Usually lower investment than CIP systems, COP systems deliver consistent results, provide a cost savings over manual cleanings, and saves on time, chemical, and water usage. All aspects of the cleaning procedure should be clearly defined in SOPs be they manual / CIP or COP. DEVELOP AND VALIDATE THE SAMPLING AND CHOSEN ANALYTICAL METHODS FOR THE COMPOUND(S) BEING CLEANED

  • Sampling

In developing the sampling plan for a validation study, it makes scientific sense to incorporate an understanding of the acceptance criteria and the limitations of the sampling method relative to the surface to be sampled. The two methods of sampling generally employed are swab and / or rinse sampling. The selection of either of these techniques must be consistent with sound scientific judgment and must support the objective of the study, which is to demonstrate that the amount of residual material in the equipment has been reduced to acceptable levels.

  • Analytical methods

In order for the analytical testing of the cleaning validation samples (swabs or rinses) to yield meaningful results, the analytical methods used should be validated. This should be documented. The basic requirements are: – The ability to detect the target substance(s) at levels consistent with the acceptance criteria – The ability to detect the target substance(s) in the presence of other materials that may also be present in the sample (selectivity) EVALUATE EQUIPMENT SURFACES Determine:

  • Worst case locations to sample (swab sampling)
  • Volume and type of rinse solvent to be employed (rinse sampling)
  • Equipment surface area (necessary to calculate carryover into subsequent batches)

DEVELOP A CLEANING VALIDATION PROTOCOL FOR THE PRODUCT AND THE EQUIPMENT BEING CLEANED That should encompass for example: 1. Introduction 2. Scope 3. Equipment 4. Cleaning procedure 5. Sampling procedures 6. Analytical testing procedure 7. Acceptance/Cleaning limits. 8. Acceptance criteria for the validation. GENERATE A CLEANING VALIDATION REPORT DETAILING THE ACCEPTABILITY OF THE CLEANING PROCEDURE FOR THE EQUIPMENT AND THE PRODUCT The report should give a full detailed background and introduction to the cleaning validation study and should evaluate all data generated with respect to the acceptance criteria employed for the study. The report should also indicate the requirement, if any, for revalidation (period of time /change control etc.). If you would like PharmaLex Ireland – a PharmaLex Company to  assist your organisation , please contact us at +353 1 846 47 42 or contactirl@pharmalex.com.

Related posts
Resilience of Pharma Supply Chains and the Impact of Covid-19 Pandemic
Resilience of Pharma Supply Chains and the Impact of Covid-19 Pandemic
17th May 2021
Contamination Control
Contamination Control
8th April 2021
Rules on Ownership of Medicinal Product stock distributed in Great Britain
Rules on Ownership of Medicinal Product stock distributed in Great Britain
7th April 2021
GET SMART: reliable analytical results & continuous regulatory compliance!
GET SMART: reliable analytical results & continuous regulatory compliance!
30th March 2021
Challenges of Advanced Therapy Medicinal Products (ATMPs)
Challenges of Advanced Therapy Medicinal Products (ATMPs)
16th March 2021
Supporting M&A in the pharmaceutical / biopharmaceutical industry
Supporting M&A in the pharmaceutical / biopharmaceutical industry
11th February 2021
Search
Categories
  • All News
  • Webinars
  • Events
Archive
Biopharma Excellence Website Image

PharmaLex Brings You Biopharma Excellence

Biopharma Excellence is a fusion of three scientific powerhouses, PharmaLex, ERA Consulting and Biopharma Excellence – all under the PharmaLex brand. This global team of scientific, regulatory and commercial professionals provide strategic product development and proactive regulatory services to developers of biopharmaceuticals, cell and gene therapies, monoclonal antibodies (MABs), vaccines and biosimilars.

Visit Website
USEFUL LINKS
  • Home
  • Contact us
  • Imprint
  • Data Protection
  • Terms and Conditions
RECENT TWEETS
PharmaLexGLOBALPharmaLex@PharmaLexGLOBAL·
12 May

Patrick Nieuwenhuizen talks to BioPharm International about the Limitations of Sterility Testing and understanding the challenges and solutions of Aseptic Processing.

Read more: https://lnkd.in/d8cq4V6u

#sterilitytesting #asepticprocessing #pharma

COVID-19 NEWSLETTER SIGN UP

SIGN UP NOW

WHAT OUR CLIENTS SAY
  • There was a close relationship between the regulatory strategy and the writing activities. You developed a fine-tuned regulatory strategy which will be a key factor to smooth the approval of our dossier.

    Large Pharma, Global
    VP Regulatory Strategy
PharmaLex
©2022 PharmaLex GmbH. All rights reserved.

ISO9001:2015 LogoEnergie Audit LogoSGS Logo

Suspicious Emails

We are aware of a number of suspicious emails about recruitment in circulation purporting to be from PharmaLex. Emails sent by PharmaLex will originate from @pharmalex.com. Should you receive an email and are unsure as to its validity, please report it to contact@pharmalex.com.

Many thanks for your understanding.

The PharmaLex Team

    Please DO NOT send us event/conference information.
    We will not respond and these will be deleted immediately.





    Select your state:

    .
    If you do not wish to receive any communication from us, you may unsubscribe at any time.

    #AskTheExpert #TogetherBEYONDCOVID19





      Select your state:

      .
      You can unsubscribe at any time at data.protection@pharmalex.com

      If you do not wish to receive any communication from us, you can unsubscribe at any time at. Click here to view our Privacy Policy.

      #TogetherBEYONDCOVID19

      We closely monitor developments and updates surrounding the current outbreak of Coronavirus Disease 2019 (COVID-19) from official sources including the World Health Organisation and are following the guidance and direction of the governments and the local authorities. We are taking this situation very seriously and our number one priority is the safety and business continuity for our customers and colleagues. As ever, we will do everything we can to ensure that services are delivered within the required time and the trusted quality PharmaLex is known for